81 related articles for article (PubMed ID: 20950605)
21. B-Lymphocyte stimulator: a new biomarker for multiple myeloma.
Jiang P; Yueguo W; Huiming H; Hongxiang Y; Mei W; Ju S
Eur J Haematol; 2009 Apr; 82(4):267-76. PubMed ID: 19187273
[TBL] [Abstract][Full Text] [Related]
22. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.
Marín YE; Wall BA; Wang S; Namkoong J; Martino JJ; Suh J; Lee HJ; Rabson AB; Yang CS; Chen S; Ryu JH
Melanoma Res; 2007 Oct; 17(5):274-83. PubMed ID: 17885582
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of HOXA9 expression by nuclear factor kappa B (NF-kappaB) and HOXA9.
Trivedi CM; Patel RC; Patel CV
Gene; 2008 Jan; 408(1-2):187-95. PubMed ID: 18068911
[TBL] [Abstract][Full Text] [Related]
24. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.
Choi BH; Kim CG; Lim Y; Shin SY; Lee YH
Cancer Lett; 2008 Jan; 259(1):111-8. PubMed ID: 18006147
[TBL] [Abstract][Full Text] [Related]
25. In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation.
Griffin BD; Moynagh PN
Biochem J; 2006 Nov; 400(1):115-25. PubMed ID: 16792530
[TBL] [Abstract][Full Text] [Related]
26. Polyglutamine-expanded ataxin-7 decreases nuclear translocation of NF-kappaB p65 and impairs NF-kappaB activity by inhibiting proteasome activity of cerebellar neurons.
Wang HL; He CY; Chou AH; Yeh TH; Chen YL; Li AH
Cell Signal; 2007 Mar; 19(3):573-81. PubMed ID: 17005371
[TBL] [Abstract][Full Text] [Related]
27. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.
Sharma C; Kaur J; Shishodia S; Aggarwal BB; Ralhan R
Toxicology; 2006 Nov; 228(1):1-15. PubMed ID: 16996673
[TBL] [Abstract][Full Text] [Related]
28. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Fu L; Lin-Lee YC; Pham LV; Tamayo A; Yoshimura L; Ford RJ
Blood; 2006 Jun; 107(11):4540-8. PubMed ID: 16497967
[TBL] [Abstract][Full Text] [Related]
29. B type CpG-DNA suppresses poly(I:C)-induced BLyS expression and production in human tonsillar fibroblasts.
Yamada T; Jiang X; Kubo S; Sakashita M; Narita N; Yamamoto H; Sunaga H; Fujieda S
Clin Immunol; 2011 Dec; 141(3):365-71. PubMed ID: 22015147
[TBL] [Abstract][Full Text] [Related]
30. BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells.
Zhu J; Sun L; Lin S; Zhao R; Zhou L; Fang D; Chen L; Liu J; Shi W; Zhang L; Yuan S
J Exp Clin Cancer Res; 2012 Mar; 31(1):31. PubMed ID: 22463935
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.
Rajitha B; Belalcazar A; Nagaraju GP; Shaib WL; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Cancer Lett; 2016 Apr; 373(2):227-33. PubMed ID: 26850372
[TBL] [Abstract][Full Text] [Related]
32. Curcumin protects against collagen-induced arthritis via suppression of BAFF production.
Huang G; Xu Z; Huang Y; Duan X; Gong W; Zhang Y; Fan J; He F
J Clin Immunol; 2013 Apr; 33(3):550-7. PubMed ID: 23184090
[TBL] [Abstract][Full Text] [Related]
33. Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice.
Schmidt MR; Appel MC; Giassi LJ; Greiner DL; Shultz LD; Woodland RT
PLoS One; 2008 Sep; 3(9):e3192. PubMed ID: 18784835
[TBL] [Abstract][Full Text] [Related]
34. Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody.
Zhuang W; Zhang J; Pei L; Fang S; Liu H; Wang R; Su Y
Mol Immunol; 2016 Sep; 77():141-7. PubMed ID: 27505709
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue.
Katsori AM; Palagani A; Bougarne N; Hadjipavlou-Litina D; Haegeman G; Vanden Berghe W
Molecules; 2015 Jan; 20(1):863-78. PubMed ID: 25580684
[TBL] [Abstract][Full Text] [Related]
36. An optimized B lymphocyte stimulator (BLyS) antagonist peptide inhibits the interaction of BLyS with BCMA.
Tian Y; Zhu YF; Wu Z; Feng JN; Li Y; Shen BF; Sun J
Biotechnol Lett; 2013 Apr; 35(4):523-8. PubMed ID: 23242501
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory and therapeutic activity of curcumin.
Srivastava RM; Singh S; Dubey SK; Misra K; Khar A
Int Immunopharmacol; 2011 Mar; 11(3):331-41. PubMed ID: 20828642
[TBL] [Abstract][Full Text] [Related]
38. Multiple molecular targets in cancer chemoprevention by curcumin.
Thangapazham RL; Sharma A; Maheshwari RK
AAPS J; 2006 Jul; 8(3):E443-9. PubMed ID: 17025261
[TBL] [Abstract][Full Text] [Related]
39. Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.
Gachpazan M; Habbibirad S; Kashani H; Jamialahmadi T; Rahimi HR; Sahebkar A
Adv Exp Med Biol; 2021; 1291():41-53. PubMed ID: 34331683
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases.
Stohl W
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):351-8. PubMed ID: 17214581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
